Introduction: Serum CA15-3 has been one of the most reliable tumor markers used in monitoring of breast cancer patients. To increase its sensitivity, the combined measurement of other tumor markers (CEA and ferritin) with CA15-3 was investigated. The aim of this study was determination of CA 15-3, CEA and ferritin in female patients with breast cancer, lung cancer and mastitis Methods: 300 patients with carcinoma, hospitalized at Department of Gynecologic Oncology and Department for Oncology at the University Clinics Center of Sarajevo and 200 healthy subjects were compared. Results: In patients with breast cancer the mean value of tumor markers were CEA 155.61 ng/mL, CA 15-3 106.38 U/mL and ferritin 197.03 ng/mL. In patients with lung cancer CEA was 58.97 ng/ml, CA 15-3 40.62 U/ mL and ferritin 544.16 ng/mL. Patients with mastitis had CEA 5.17 ng/mL, CA 15-3 112.67 U/mL and ferritin 174.92 ng/mL. The control group had values of tumor markers CEA 1.62 ng/mL, CA 15-3 11.72 U/mL and ferritin 85.35 ng/mL. We found good correlation between CA 15-3 and CEA correlation coeffi cient was r = 0.750. There was a low correlation between CA 15-3 and ferritin with correlation coeffi cient r = 0.274.
Introduction
Although the measurement of tumor markers in breast cancer has been studied for nearly 20 years, their usefulness remains unclear. In patients with metastatic breast carcinoma, tumor markers appear to be useful during follow-up, but a wide range in rates of marker positivity has been reported: 50%-80% (1) (2) (3) . Breast cancer is the most common malignancy in women. Successful treatment of breast cancer relies on a better understanding of the molecular mechanisms involved in breast cancer initiation and progression (4) . Th e CA 15-3 concentrations increase was observed in various malignant tumors, but this is a useful marker for breast cancer metastasis and is determined in monitoring disease progression and success of therapy. It is not used as screening test or as a test for primary diagnosis because it has low diagnostic sensitivity (5) . CA 15-3 alone, however, is not recommended as a marker for either diagnosis or detection of early recurrence of breast cancer according to the American Society of Clinical Oncology (ASCO) guidelines (6) . Because of insuffi cient data, the ASCO also does not recommend the use of CA 15-3 alone as a marker for monitoring response. It should be noted that the elevation of CA 15-3 between 4 and 6 weeks aft er initiation of a new therapy, i.e. spurious early rise (surge), indicates poor prognosis. Th e proportion of patients exhibiting a surge in CA 15-3 level aft er chemotherapy initiation was reported to be 4.8%, and patients with surge may respond more poorly to chemotherapy than those without surge (7) . CEA is also not recommended as a marker for diagnosis or routine surveillance aft er primary therapy, and a surge in CEA level may also occur between 4 and 6 weeks aft er initiation of primary treatment. Th e ASCO does not recommend CEA measurement in patients with positive CA 15-3; thus, the CEA level provides only supplementary information. However, if suffi cient data regarding other factors are available, rising CEA level can be a useful indicator of treatment failure in patients without measurable disease (8) . Eff orts are directed to identify new markers of breast cancer, which might be used for early detection, staging and prognosis, and prediction of therapy response. Ferritin is a large macromolecule (450 kDa) which is synthesized in the liver, spleen, myocardium, placenta and other tissues and plays a major role in iron storage. It consists of 24 subunits which form protein shell (apoferritin) around an insoluble core of stored iron. Th ere are two types of subunits, the basic L and acidic H type. Different isoferritins have diff erent proportions of these two subunits (9) . Ferritin is a sensitive indicator of iron defi ciency, thus the main clinical application of serum ferritin measurement is in diff erential diagnosis of anaemia. Ferritin concentration may increase in case of iron overload (haemochromatosis or haemosiderosis), infection or infl ammation, neurodegenerative disorders, malignancies and destruction of liver tissue (10) . Ferritin is one of the proteins whose concentration may be altered due to breast cancer presence. Recent studies have suggested a crucial role of perturbations in ferritin levels and tightly associated with this, the deregulation of intracellular iron homeostasis; however, the underlying molecular mechanisms for the cancer-linked ferritin alterations remain largely unknown and oft en with confl icting conclusions (11) . Th erefore, this study was undertaken to defi ne the role of ferritin in breast cancer. We have make determination of CA 15-3, CEA and ferritin at patents with breast or lung cancer and patients with diagnosis of mastitis. At our investigation we try to fi nd a possible correlation between tumor marker CA 15-3 with tumor marker CEA and ferritin in patients with cancer.
Methods

Patients
Th e investigation included patients (n= 500) in period from February till October in 2011. It was retrospective study ant we included female patients with diagnosis breast cancer, lung cancer or with diagnosis of mastitis. All of 300 patients were hospitalized at Department of Gynecologic Oncology and Department for Oncology at the University Clinics Center of Sarajevo and 200 healthy subjects. Th e mean age of patients with cancer was 45.32-/+ 9.23, patents with mastitis 35.24 +/-5.64 and mean age of control group was 43.45 -/+ 2.85. Th e patient samples of blood were collected in serum separation Vacutainer test tubes (Beckton Dickinson, Rutherford, NJ 07,070 U.S.) in volume of 3.5 mL. We used test tubes with gel. Serum samples were obtained by centrifugation at 3000 rpm using centrifuge (Sigma 4-10). Aft er centrifuging, serum concentration of CEA, CA 15-3 and ferritin was determined. Th e investigation was done respecting ethical standards in the Helsinki Declaration.
Chemiluminescent microparticle immunoassay -CMIA
All immunoassays require the use of labeled material in order to measure the amount of antigen or antibody. A label is a molecule that will react as a part of the assay, so a change in signal can be measured in the blood aft er added reagent solution. CMIA is noncompetitive sandwich assay technology to measure analytes. Th e amount of signal is directly proportional to the amount of analyte present in the sample. Architect ferritin, CEA and CA 15-3 assay is twostep immunoassay to determine the presence antigen in human serum using CMIA technology. In the fi rst step, sample, assay diluent and anti-antibody-coated paramagnetic particles are combined. Ferritin, CEA or CA 15-3 present in the sample binds to the anti-coated micro particles. Aft er incubation and wash, anti-acridiniumlabeled conjugate is added in the second step. Following another incubation and wash, pre-trigger and trigger solutions are then added to the reaction mixture. Th e pre-trigger solution (hydrogen peroxide) performs the following functions:
• Creates an acidic environment to prevent NAFIJA SERDAREVIĆ, SAMIRA MEHANOVIĆ: THE POSSIBLE ROLE OF TUMOR ANTIGEN CA 15-3, CEA AND FERRITIN IN MALIGNANT AND BENIGN DISEASE early release of energy (light emission).
• Helps to keep microparticles from clumping.
• Splits acridinium dye off the conjugate bound to the microparticle complex. Th is action prepares the acridinium dye for the next step. Th e trigger solution (sodium hydroxide) dispenses to the reaction mixture. Th e acridinium undergoes an oxidative reaction when exposed to peroxide and an alkaline solution. Th is reaction causes the chemiluminescent reaction to occor. N-methylacridone forms and releases energy (light emission) as it returns to its ground state. Th e resulting chemiluminescent reaction is measured as relative light units (RLU). A direct relationship exists between the amount of ferritin, CEA or CA 15-3 in the sample and RLU detected by Architect System optics (8) . Th e normal serum range of CA 15-3 between 0. 0 -31.3 U/mL, CEA 0-5.00 ng/mL and ferritin 4.63 -204.00 ng/mL. Statistical analysis Th e results were statistically analyzed using NCSS and statistical soft ware SPSS version 12.0 soft ware. Determined by the average value ( ), standard deviation (SD), Pearson correlation coeffi cient (r), equations of linear regression and Student t test with statistical signifi cance level of p <0.05.
Results
Th e CA 15-3 is cancer antigen that is used in the management of some patients with breast cancer. It is most eff ective at monitoring metastatic breast cancer, but has not had high success at detecting early stage breast cancers. Many studies are still conducted with the purpose of fi nding markers that could be used for early diagnosis and/or serve as possible reliable prognostic or predictive parameters, but with confl icting results. At present, no markers are available for an early diagnosis of breast cancer. Th e surveillance of patients with diagnosed breast cancer the most widely used serum markers are CA 15-3 and CEA which, in combination with other clinical parameters, could have clinical signifi cance. Th e raised of serum ferritin concentrations in breast carcinoma patients might be attributed to stromal reaction rather than to tumor synthesis. In our study we have a female patients with diagnosis of breast and lung cancer. Th e patients with lung cancer have a primary cancer in breast. Th e patients with cancer were hospitalized in Department of Gynecologic Oncology and Department for Oncology at the University Clinics Center of Sarajevo. Th e patients with mastitis were hospitalized in Department of Gynecologic at the University Clinics Center of Sarajevo. Th e percent of patients in our study is show in Figure 1 . Abnormal CEA (>5 ng/mL) or CA 15.3 (>30 U/ mL) serum concentrations were found in 15.4% and 27.2 % of the patients studied, respectively. In patients with breast cancer the mean value of tumor markers were CEA 155.61 ng/mL, CA 15-3 106.38 U/mL and ferritin 197.03 ng/mL. Our study have got results in patient with lung cancer CEA 58.97 ng/ml, CA 15-3 40.62 U/mL and ferritin 544.16 ng/mL. Th e results of our study have shown that the patients with mastitis have CEA 5.17 ng/mL, CA 15-3 112.67 U/mL and ferritin 174.92 ng/mL. Th e control groups have value of tumor markers CEA 1.62 ng/mL, CA 15-3 11.72 U/mL and ferritin 85.35 ng/mL. Serum levels for the three tumor markers in patients with metastatic diseases were signifi cantly higher than those in patients without metastasis. Th is suggests that serum CA15-3 is the most reliable monitoring marker in patients with metastatic diseases. Th e CEA and ferritin were high in patients with lung cancer then CA 15-3 and it could be explain that CEA is more specifi c for lungs then CA 15-3. Th e raises serum ferritin in tumors might be due to tumor synthesis because the ferritin is reactant of acute phase. Th e mean value of tumor marker in our study is shown in Figure 2 . We compared CA 15-3 and ferritin in patients with 
Discussion
Th e results of this study indicate that of the three tumor markers tested, serum CA15-3 is the most sensitive and specifi c in terms of the detection of breast cancer metastases. In our study the average concentration of CEA and CA 15-3 was higher in patients group with primary breast cancer, a results are shown in Figure 2 . Th e CA 15-3 was higher in breast cancer but lower than CEA in lung cancer. Th e patients with mastitis diagnosis the have higher concentration of CA 15-3 but normal concentration of CEA. Serum CA15-3 has been one of the most reliable tumor markers used in monitoring breast cancer patients. It has been reported that the sensitivity and specifi city of serum CA15-3 for detecting metastatic diseases are higher than those of CEA (12, 13) .
In our study the concentration of CEA was mostly elevated in patients with breast and lung carcinoma. Th e recent study has reported that serum levels of CEA were high at patients with adenocarcinoma and squamous carcinoma (14) . Th e other investigator has shown that CEA is signifi cantly related to diff erential degree of lung cancers (15). Th e diff erent staining patterns and positive rates and intensities of CEA may be helpful for the pathological classifi cation of lung cancers. Th e CEA concentration was in reference rage in patients with mastitis and controls. In this study patients with cancer particularly with lung cancer have higher concentration of ferritin. Th is might be due to the potential additional regulators involved in ferritin synthesis. Iron is the main, but not the only regulator of ferritin expression. Hypoxia, oft en present in neoplastic tissue, is also one of the factors that promote ferritin increase independently of the iron status (16, 17) . Th e ferritin concentrations may be a prognostic indicator in some patients with lungs and breast cancer. In this study the highest levels of ferritin were obtained in the group of patients with advanced disease, which was in agreement with previous reports (18) . Th e other study groups have found that ferritin has been previously associated with breast cancer. Still, there is no consistent conclusion regarding its role or relevance in breast cancer (19) . Th e possible limitation of our study is that we do not have information about ferritin level in patients before cancer or mastitis. Linear regression analysis of the values for the tumor markers revealed that serum CA 15-3 values were not correlated with serum ferritin values (r = 0.274) but it was good correlation with serum CEA values (r =0.750). Th e correlation results are shown in Figure 3 and 4. In other investigation groups it was found that good correlation between CA 15-3 and CEA with coeffi cient of correlation r = 0.96 (20) .
Conclusion
Serum concentrations of CEA, CA 15-3, are related to tumor extent, with signifi cantly higher values seen in patients with breast cancer. Th e CA 15-3 is only specifi c in patients with metastasis because we have got high concentration in patients with mastitis. Th e serum value of CEA was higher in patients with lung cancer. Further prospective studies, of a large number of subjects premenopausal and postmenopausal women, are required to confi rm such a statement and to validate the usefulness of ferritin determination in the serum of lung or breast cancer patients.
Confl ict of interest
Authors declare no confl ict of interest.
